TScan Therapeutics Up 5% On FDA Clearance For TSC-203-A0201

Shares of TScan Therapeutics, Inc. (TCRX) are up 5% on Tuesday after the company announced that it received FDA clearance for its IND application for TSC-203-A0201, a TCR-T targeting PReferentially expressed Antigen in Melanoma (PRAME).

Related Keywords

Gavin Macbeath ,Tscan Therapeutics Inc ,Nasdaq , ,Wind ,Tscan Therapeutics ,Frame ,Pcrx ,